|
시장보고서
상품코드
1890922
뇌종양 치료 시장 : 치료법별, 종양 유형별, 약제 분류별, 연령층별, 성별, 최종사용자별, 유통 채널별, 지역별Brain Tumor Treatment Market, By Treatment Modality, By Tumor Type, By Drug Class, By Age Group, By Gender, By End User, By Distribution Channel, By Geography |
||||||
뇌종양 치료 시장은 2025년에 23억 4,000만 달러로 추정되며, 2032년까지 45억 3,000만 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 9.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 커버 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 23억 4,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 9.90% | 2032년 예측 가치 : | 45억 3,000만 달러 |
세계 뇌종양 치료 시장은 중추신경계에 영향을 미치는 가장 복잡하고 어려운 질병 중 하나를 다루는 광범위한 종양 치료 분야에서 중요한 부문입니다.
뇌종양은 뇌 조직내 또는 그 주변에서 비정상적인 세포 증식을 특징으로 하며, 뇌에서 유래한 원발성 종양과 다른 부위에서 전이된 이차성 종양을 모두 포함합니다. 치료 패러다임은 수술적 개입, 방사선 치료, 화학요법, 표적치료, 그리고 새로운 면역치료 옵션을 결합한 다각적인 접근법을 채택하고 있으며, 각각의 치료법은 특정 종양 유형, 발생 부위 및 환자 상태에 따라 조정됩니다.
이 시장의 중요성은 기존 치료법을 넘어 정위적 방사선 수술, 종양 치료용 전기장, 분자 프로파일링에 기반한 맞춤형 의료와 같은 첨단 기술까지 포괄하고 있습니다. 전 세계 뇌종양 발생률 증가, 고령화, 진단 기술의 발전으로 효과적인 치료 솔루션에 대한 수요가 증가하고 있습니다.
치료 계획에 인공지능의 통합, 혈액뇌관문 투과성 약물의 개발, 최소침습 수술 기술의 발전으로 치료 프로토콜을 재구성하고 있습니다. 전 세계 의료 시스템은 신경종양 전문센터와 첨단 장비에 대한 투자를 확대하고 있으며, 제약사들은 이 어려운 치료 영역에서 미충족 의료 수요를 충족시키기 위해 연구개발에 박차를 가하고 있습니다.
시장 역학
세계 뇌종양 치료 시장은 여러 가지 강력한 촉진요인에 의해 성장 궤도를 형성하고 있으며, 동시에 여러 가지 제약 요인에 직면하고 있으며, 이해관계자들에게 큰 기회를 제공합니다. 주요 시장 성장 촉진요인으로는 전 연령대에서 뇌종양 발생률 증가, 특히 다양한 종양 유형에 취약한 고령 인구 증가, 조기 진단 및 치료 옵션에 대한 환자 및 의료 서비스 프로바이더의 인식 증가가 꼽힙니다.
고해상도 MRI, PET 스캔, 분자진단 등 첨단 진단기술로 보다 조기에 정밀하게 종양을 발견할 수 있게 되어 치료 수요를 견인하고 있습니다. 표적치료, 면역치료, 유전자 프로파일링에 기반한 맞춤의료와 같은 새로운 치료법의 급속한 발전은 치료의 가능성을 넓히고 환자들의 치료 성적을 향상시키고 있습니다. 그러나 뇌종양 치료에는 매우 높은 비용이 수반된다는 점이 큰 제약 요인으로 작용하고 있습니다. 많은 경우, 장기적인 복합 치료 접근법, 특수 의료기기, 장기 입원이 필요하며, 이는 환자와 의료 시스템에 경제적 장벽으로 작용하고 있습니다.
혈액 뇌 장벽은 생물학적으로 중요한 문제로, 약물전달의 효과를 제한하고 치료 옵션을 제한합니다. 또한 뇌종양의 복잡한 해부학적 부위는 수술적 개입을 본질적으로 위험하게 만들고 때로는 불가능하게 만들기도 합니다. 새로운 치료법에 대한 엄격한 규제 승인 과정과 희귀 뇌종양 유형의 환자 수가 상대적으로 적다는 점은 제약사에게 또 다른 과제를 안겨주고 있습니다.
본 조사의 주요 특징
- 세계의 뇌종양 치료 시장에 대한 상세한 분석과 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 CAGR%를 조사하여 예측한 보고서입니다.
- 또한 다양한 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명할 것입니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 뇌종양 치료제 시장의 주요 업체를 프로파일링합니다.
- 본 조사에서 다루는 주요 기업은 F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc., Pfizer Inc., Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca PLC, y-Mabs Therapeutics Inc., Emcure Pharmaceuticals Ltd., NextSource Pharmaceuticals LLC, and Daiichi Sankyo Co., Ltd.입니다.
- 이 보고서는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 뇌종양 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 뇌종양 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 뇌종양 치료 시장 : 치료법별, 2020-2032년
- 화학요법(예 : 알킬화제, 세포 독성약제)
- 방사선 요법(예 : 외부 조사, 정위방사선 수술)
- 표적치료(예 : 분자 표적형 저분자화합물)
- 면역치료(예 : 체크포인트 저해제, CAR-T 요법)
- 기타 치료법(예 : 종양 치료 전기장, 유전자 치료, 병용요법)
제5장 세계의 뇌종양 치료 시장 : 종양 유형별, 2020-2032년
- 원발성 뇌종양(예 : 교아종, 별세포종)
- 전이성/2차성 뇌종양
- 수막종
- 하수체 종양
- 기타 종양 유형(예 : oligodendroglioma, ependymoma)
제6장 세계의 뇌종양 치료 시장 : 약제 분류별, 2020-2032년
- 알킬 화 제
- 대사 길항제
- 모노클로널 항체
- 저분자 저해제
- 기타 약제 분류(예 : 프로테아좀 저해제, 에피제네틱 조절제)
제7장 세계의 뇌종양 치료 시장 : 연령층별, 2020-2032년
- 소아
- 성인
- 고령자
제8장 세계의 뇌종양 치료 시장 : 성별, 2020-2032년
- 남성
- 여성
제9장 세계의 뇌종양 치료 시장 : 최종사용자별, 2020-2032년
- 병원 및 종합 암센터
- 외래 수술 센터/외래 진료 센터
- 전문 클리닉(신경 종양학 클리닉)
- 재택 의료/원격의료 환경(해당하는 경우)
제10장 세계의 뇌종양 치료 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 뇌종양 치료 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylana€¯NN.V.(now Viatris)
- Mercka€¯NKGaA
- BristolMyers Squibb Company
- Grunenthal GmbH
- Sanofi S.A.
- AbbVie Inc.
제13장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Brain Tumor Treatment Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 4.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 2.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.90% | 2032 Value Projection: | USD 4.53 Bn |
The global brain tumor treatment market represents a critical segment within the broader oncology therapeutics landscape, addressing one of the most complex and challenging medical conditions affecting the central nervous system.
Brain tumors, characterized by abnormal cell growth within or around the brain tissue, encompass both primary tumors originating in the brain and secondary metastatic tumors spreading from other body parts. The treatment paradigm involves a multidisciplinary approach combining surgical interventions, radiation therapy, chemotherapy, targeted therapy, and emerging immunotherapy options, each tailored to specific tumor types, locations, and patient conditions.
The market's significance extends beyond traditional therapeutic modalities, incorporating advanced technologies such as stereotactic radiosurgery, tumor-treating fields, and personalized medicine approaches based on molecular profiling. Rising incidence rates of brain tumors globally, coupled with an aging population and improved diagnostic capabilities, have intensified the demand for effective treatment solutions.
The integration of artificial intelligence in treatment planning, development of blood-brain barrier penetrating drugs, and advancement in minimally invasive surgical techniques are reshaping treatment protocols. Healthcare systems worldwide are increasingly investing in specialized neuro-oncology centers and cutting-edge equipment, while pharmaceutical companies are accelerating research and development efforts to address unmet medical needs in this challenging therapeutic area.
Market Dynamics
The global brain tumor treatment market is propelled by several compelling drivers that continue to shape its growth trajectory, while simultaneously facing notable restraints and presenting significant opportunities for stakeholders. The primary market drivers include the escalating global incidence of brain tumors across all age groups, with particular emphasis on the growing geriatric population that exhibits higher susceptibility to various tumor types, alongside increasing awareness about early diagnosis and treatment options among patients and healthcare providers.
Advanced diagnostic technologies such as high-resolution MRI, PET scans, and molecular diagnostics are enabling earlier and more precise tumor detection, subsequently driving treatment demand. The rapid development of novel therapeutic approaches, including targeted therapies, immunotherapies, and personalized medicine based on genetic profiling, is expanding treatment possibilities and improving patient outcomes. However, the market faces substantial restraints including the extremely high costs associated with brain tumor treatments, which often require prolonged multi-modal therapy approaches, specialized equipment, and extended hospitalization periods that create financial barriers for patients and healthcare systems.
The blood-brain barrier presents a significant biological challenge, limiting drug delivery effectiveness and reducing therapeutic options, while the complex anatomical location of brain tumors makes surgical interventions inherently risky and sometimes impossible. Stringent regulatory approval processes for new therapies, coupled with the relatively small patient population for rare brain tumor types, create additional challenges for pharmaceutical companies.
Key Features of the Study
- This report provides in-depth analysis of the global brain tumor treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global brain tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered in this study include F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc., Pfizer Inc., Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca PLC, y-Mabs Therapeutics Inc., Emcure Pharmaceuticals Ltd., NextSource Pharmaceuticals LLC, and Daiichi Sankyo Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global brain tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain tumor treatment market
Market Segmentation
- Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
- Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
- Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
- Targeted Therapy (e.g., molecularly targeted small molecules)
- Immunotherapy (e.g., checkpoint inhibitors, CAR T therapies)
- Other Therapies (e.g., tumor treating fields, gene therapy, combination modalities)
- Tumor Type Insights (Revenue, USD Bn, 2020 - 2032)
- Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
- Metastatic/Secondary Brain Tumors
- Meningioma
- Pituitary Tumors
- Other Tumor Types (e.g., oligodendroglioma, ependymoma)
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Alkylating Agents
- Antimetabolites
- Monoclonal Antibodies
- Small Molecule Inhibitors
- Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Integrated Cancer Centers
- Ambulatory Surgical/Outpatient Centers
- Specialty Clinics (neuro oncology clinics)
- Home Care/Remote Care Settings (where applicable)
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals plc
- Sun Pharmaceutical Industries Ltd.
- Johnson and Johnson
- Viatris Inc.
- Hikma Pharmaceuticals plc
- Aurobindo Pharma Ltd.
- Endo International plc
- Mylan N.V. (now Viatris)
- Merck KGaA
- Bristol Myers Squibb Company
- Grunenthal GmbH
- Sanofi S.A.
- AbbVie Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Brain Tumor Treatment Market, By Treatment Modality
- Global Brain Tumor Treatment Market, By Tumor Type
- Global Brain Tumor Treatment Market, By Drug Class
- Global Brain Tumor Treatment Market, By Age Group
- Global Brain Tumor Treatment Market, By Gender
- Global Brain Tumor Treatment Market, By End User
- Global Brain Tumor Treatment Market, By Distribution Channel
- Global Brain Tumor Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Brain Tumor Treatment Market, By Treatment Modality, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Targeted Therapy (e.g., molecularly targeted small molecules)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunotherapy (e.g., checkpoint inhibitors, CART therapies)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Therapies (e.g., tumortreating fields, gene therapy, combination modalities)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Brain Tumor Treatment Market, By Tumor Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metastatic/Secondary Brain Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Meningioma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pituitary Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Tumor Types (e.g., oligodendroglioma, ependymoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Brain Tumor Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Alkylating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- SmallMolecule Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Brain Tumor Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Brain Tumor Treatment Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Brain Tumor Treatment Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Integrated Cancer Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical/Outpatient Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics (neurooncology clinics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Care/Remote Care Settings (where applicable)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Brain Tumor Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Brain Tumor Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylana€¯N.V. (now Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mercka€¯KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BristolMyers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grunenthal GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
